Table 2.
Treatments and outcomes of COVID-19 patients with non-DM or DM.
| Total (n = 288) | Non-DM (n = 264) | DM (n = 24) | P values | |
|---|---|---|---|---|
| Treatments | ||||
| Antiviral | 233 (80.9%) | 215 (81.4%) | 18 (75%) | 0.442 |
| Antibiotics | 244 (84.7%) | 223 (84.5%) | 21 (87.5%) | 0.693 |
| Vasoactive drugs | 5 (1.7%) | 4 (1.5%) | 1 (4.2%) | 0.341 |
| Glucocorticoid | 21 (7.3%) | 19 (7.2%) | 2 (8.3%) | 0.838 |
| Oxygen inhalation | ||||
| None | 88 (30.6%) | 82 (31.1%) | 6 (25.0%) | 0.537 |
| Normal-flux | 184 (63.9%) | 168 (63.6%) | 16 (66.7%) | 0.767 |
| High-flux | 16 (5.6%) | 14 (5.3%) | 2 (8.3%) | 0.535 |
| Tracheal intubation | 8 (2.8%) | 6 (2.3%) | 2 (8.3%) | 0.084 |
| CPAP | 32 (11.1%) | 28 (10.6%) | 4 (16.7%) | 0.366 |
| CRRT | 5 (1.7%) | 4 (1.5%) | 1 (4.2%) | 0.341 |
| ECMO | 4 (1.4%) | 3 (1.1%) | 1 (4.2%) | 0.225 |
| Glycemic control therapy | ||||
| Use of insulin | NA | NA | 6 (25%) | NA |
| Oral glucose control agents | NA | NA | 15 (62.5%) | NA |
| Combined | NA | NA | 3 (12.5%) | NA |
| Outcomes | ||||
| Admission to ICU | 27 (9.4%) | 22 (8.3%) | 5 (20.8%) | 0.044 |
| ARDS | 3 (1.0%) | 2 (0.8%) | 1 (4.2%) | 0.115 |
| Clinical typesa (severe/critically severe) | 30 (10.4%) | 25 (9.5%) | 5 (20.8%) | 0.048 |
Data are presented as median (interquartile range) or number (percent). Abbreviations: NA: not applicable; CPAP: continuous positive airway pressure ventilation; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; ARDS: Acute Respiratory Distress Syndrome. aClinical types (severe/critically severe) were based on the notice on the issuance of a program for the diagnosis and treatment of novel coronavirus- (2019-nCoV-) infected pneumonia (7th edition) published by the General Office of National Health Committee.